On May 21, ImmunityBio rose 5.03% in regular trading, trading at $8.15/share, with trading volume of $180 million. The stock continues to gain momentum following a series of positive developments announced in recent days.

At the 2026 American Urological Association Annual Meeting, ImmunityBio presented positive efficacy comparison data showing its ANKTIVA (Nai) plus BCG therapy demonstrated favorable complete response rates compared with Nadofaragene and TAR-200 therapies. Additionally, the company received five US patents covering the combination of its IL-15 receptor agonist ANKTIVA with BCG for cancer treatment, with validity extending until at least 2035. These patents protect the product, dosing regimen, commercial kit, and treatment methods for non-muscle invasive bladder cancer.

Further bolstering sentiment, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory to obtain rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, backed by Phase 3 data demonstrating non-inferiority to TICE BCG.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)